Most Read Articles
2 years ago
A study on participants from the Women's Health Initiative showed the dissociation between calcium/vitamin D supplementation and reduction in menopausal symptoms.
one year ago
Dr Lesley Braun, Blackmores Institute Director, is interviewed and answers some critical questions on complementary medicine, its evolution, its benefits and its present and future roles alongside mainstream medicine.
Pearl Toh, 12 days ago
Elderly persons (≥75 years) on aspirin-based antiplatelet therapy without routine proton-pump inhibitor (PPI) use have a higher long-term risk of major bleeding, in particular upper gastrointestinal (GI) bleeding which is often more disabling or fatal than in younger persons, according to the OXVASC* study.
Pearl Toh, 2 months ago
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.

ENABLEX Now Approved in Malaysia

2 years ago
Reclassification of MIMS Class – ENABLEX
In MIMS 140th edition (1st Issue 2015), there was an error classifying Enablex under 10f. Other Drugs Acting on the Genito-Urinary System. With effect from MIMS 141st edition (2nd Issue 2015), Enablex will be reclassified under 10e. Drugs for Bladder & Prostate Disorder to reflect a more accurate classification based on its therapeutic use.


ENABLEX – Darifenacin Hydrobromide 7.5mg Prolonged Release Tablet
 A highly selective M3 antagonist developed for treating overactive bladder (OAB) 1, 2
• Improves Incontinence Episodes (IEs) per week, Urgency Episodes (UEs) per day and micturitions per day in OAB patients with 5-50 episodes of incontinence per week 3
• No significant effect on heart rate 4
• Does not prolong the QT/QTc interval 5
• Does not impair memory or other cognitive functions 6
 
References:
1. KAY G, WESNES K. 2005. Pharmacodynamic effects if darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU International; 96:1055-62.
2. ENABLEX® Package Insert.
3. CHAPPLE C, STEERS W, NORTON P, MILLARD R, KRALIDIS G, GLAVIND K, et al. 2005. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU International; 95:993-1001.
4. OLSHANSKY B, EBINGER U, BRUM J, EGERMARK M, VIEGAS A, REKEDA L. 2008. Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years. J Cardiovasc Pharmacol Ther; doi:10.1177/1074248408325404.
5. SERRA D, AFFRIME M, BEDIGIAN M, GREIG G, MILOSAVLJEV S, SKERJANEC A, et al. 2005. QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M3 Selective Receptor Antagonist for the Treatment of Overactive Bladder. J Clin Pharmacol ; 45:1038-1047
6. KAY G, EBINGER U. 2008. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract; 62(11):1792-1800.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
2 years ago
A study on participants from the Women's Health Initiative showed the dissociation between calcium/vitamin D supplementation and reduction in menopausal symptoms.
one year ago
Dr Lesley Braun, Blackmores Institute Director, is interviewed and answers some critical questions on complementary medicine, its evolution, its benefits and its present and future roles alongside mainstream medicine.
Pearl Toh, 12 days ago
Elderly persons (≥75 years) on aspirin-based antiplatelet therapy without routine proton-pump inhibitor (PPI) use have a higher long-term risk of major bleeding, in particular upper gastrointestinal (GI) bleeding which is often more disabling or fatal than in younger persons, according to the OXVASC* study.
Pearl Toh, 2 months ago
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.